RBC Capital Reiterates Outperform Rating on NewAmsterdam Pharma Co NV (NAMS)
Tweet Send to a Friend
RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $38.00 price target on NewAmsterdam Pharma Co NV (NASDAQ: NAMS).The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
